Latest period
$47.33B
YoY change
+19.3%
5Y CAGR
+25.5%
Peak year (2025)
$48.67B
Latest annual
$48.67B
Total Equity history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $48.67B
Total Equity growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +19.3%
Total Equity history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $48.67B | +19.3% | +$7.88B | ||
| 2024 | $40.79B | +4.2% | +$1.64B | ||
| 2023 | $39.14B | +5.7% | +$2.11B | ||
| 2022 | $37.04B | -5.7% | −$2.23B | ||
| 2021 | $39.27B | +151.4% | +$23.65B | ||
| 2020 | $15.62B | +19.0% | +$2.50B | ||
| 2019 | $13.13B | +5.3% | +$659.00M | ||
| 2018 | $12.47B | -16.7% | −$2.49B | ||
| 2017 | $14.96B | +0.7% | +$106.00M | ||
| 2016 | $14.85B | -19.7% | −$3.64B | ||
| 2015 | $18.49B | -5.8% | −$1.14B | ||
| 2014 | $19.63B | -15.5% | −$3.60B | ||
| 2013 | $23.22B | -2.2% | −$513.00M | ||
| 2012 | $23.74B | +2.1% | +$491.00M | ||
| 2011 | $23.25B | +0.1% | +$33.00M | ||
| 2010 | $23.21B | +12.4% | +$2.55B | ||
| 2009 | $20.66B | +29.8% | +$4.75B | ||
| 2008 | $15.91B | +7.7% | +$1.13B | ||
| 2007 | $14.78B | -3.4% | −$526.00M | ||
| 2006 | $15.30B | +12.6% | +$1.71B | ||
| 2005 | $13.60B | -5.6% | −$807.00M | ||
| 2004 | $14.40B | +9.3% | +$1.23B | ||
| 2003 | $13.18B | +18.0% | +$2.01B | ||
| 2002 | $11.17B | -18.5% | −$2.54B | ||
| 2001 | $13.71B | +43.9% | +$4.18B | ||
| 2000 | $9.53B | -7.5% | −$769.22M | ||
| 1999 | $10.30B | +146.8% | +$6.12B | ||
| 1998 | $4.17B | +16.9% | +$602.24M | ||
| 1997 | $3.57B | +2.5% | +$87.49M | ||
| 1996 | $3.48B | +21.1% | +$607.59M | ||
| 1995 | $2.88B | +9.2% | +$241.31M | ||
| 1994 | $2.63B | +18.8% | +$417.01M | ||
| 1993 | $2.22B | +2558.1% | +$2.13B | ||
| 1992 | $83.42M | -89.3% | −$698.74M | ||
| 1991 | $782.16M | +37.0% | +$211.19M | ||
| 1990 | $570.97M | — | — |
- 2025$48.67B+19.3%
- 2024$40.79B+4.2%
- 2023$39.14B+5.7%
- 2022$37.04B-5.7%
- 2021$39.27B+151.4%
- 2020$15.62B+19.0%
- 2019$13.13B+5.3%
- 2018$12.47B-16.7%
- 2017$14.96B+0.7%
- 2016$14.85B-19.7%
- 2015$18.49B-5.8%
- 2014$19.63B-15.5%
- 2013$23.22B-2.2%
- 2012$23.74B+2.1%
- 2011$23.25B+0.1%
- 2010$23.21B+12.4%
- 2009$20.66B+29.8%
- 2008$15.91B+7.7%
- 2007$14.78B-3.4%
- 2006$15.30B+12.6%
- 2005$13.60B-5.6%
- 2004$14.40B+9.3%
- 2003$13.18B+18.0%
- 2002$11.17B-18.5%
- 2001$13.71B+43.9%
- 2000$9.53B-7.5%
- 1999$10.30B+146.8%
- 1998$4.17B+16.9%
- 1997$3.57B+2.5%
- 1996$3.48B+21.1%
- 1995$2.88B+9.2%
- 1994$2.63B+18.8%
- 1993$2.22B+2558.1%
- 1992$83.42M-89.3%
- 1991$782.16M+37.0%
- 1990$570.97M—
Total Equity values are taken from AstraZeneca's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's latest reported total equity is $47.33B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AstraZeneca (AZN) most recent annual total equity stands at $48.67B (2025) – grew 19.3% year-over-year.
AstraZeneca total equity compound annual growth for the 2020–2025 (5 years) window is +25.5%, sustaining 3 straight years of year-over-year growth.
The record annual total equity stands at $48.67B, reached in 2025; the historical low of $83.42M was recorded in 1992.
AstraZeneca Total Equity by Year
AstraZeneca Total Equity 2025: $48.67B
AstraZeneca total equity in 2025 was $48.67B, grew 19.3% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Total Equity 2024: $40.79B
2024's total equity for AstraZeneca came in at $40.79B, edged up 4.2% from 2023.
AstraZeneca Total Equity 2023: $39.14B
AstraZeneca posted total equity of $39.14B in 2023, grew 5.7% from 2022.
AstraZeneca Total Equity 2022: $37.04B
In 2022, AstraZeneca reported total equity of $37.04B, declined 5.7% below 2021.
AstraZeneca Total Equity 2021: $39.27B
AstraZeneca total equity in 2021 was $39.27B.
See more financial history for AstraZeneca (AZN).
Sector peers by Total Equity
Healthcare peers of AstraZeneca (AZN), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $53.41B | |
| $52.61B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation